Virpax Pharmaceuticals (VRPX) Competitors $0.26 +0.05 (+23.81%) As of 11:27 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRPX vs. TRVN, NMTR, ERNA, TNFA, EVFM, VIRX, WINT, MYMD, GLMD, and ENVBShould you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include Trevena (TRVN), 9 Meters Biopharma (NMTR), Eterna Therapeutics (ERNA), TNF Pharmaceuticals (TNFA), Evofem Biosciences (EVFM), Viracta Therapeutics (VIRX), Windtree Therapeutics (WINT), MyMD Pharmaceuticals (MYMD), Galmed Pharmaceuticals (GLMD), and Enveric Biosciences (ENVB). These companies are all part of the "pharmaceutical products" industry. Virpax Pharmaceuticals vs. Trevena 9 Meters Biopharma Eterna Therapeutics TNF Pharmaceuticals Evofem Biosciences Viracta Therapeutics Windtree Therapeutics MyMD Pharmaceuticals Galmed Pharmaceuticals Enveric Biosciences Virpax Pharmaceuticals (NASDAQ:VRPX) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking. Does the media favor VRPX or TRVN? In the previous week, Virpax Pharmaceuticals and Virpax Pharmaceuticals both had 2 articles in the media. Virpax Pharmaceuticals' average media sentiment score of 0.62 beat Trevena's score of 0.48 indicating that Virpax Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Virpax Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevena 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is VRPX or TRVN more profitable? Trevena's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Virpax PharmaceuticalsN/A -1,554.34% -338.29% Trevena N/A N/A -119.55% Do analysts recommend VRPX or TRVN? Virpax Pharmaceuticals currently has a consensus price target of $75.00, indicating a potential upside of 28,746.15%. Trevena has a consensus price target of $5.00, indicating a potential upside of 346.43%. Given Virpax Pharmaceuticals' higher possible upside, analysts clearly believe Virpax Pharmaceuticals is more favorable than Trevena.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals hold more shares of VRPX or TRVN? 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, VRPX or TRVN? Virpax Pharmaceuticals has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Trevena has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Which has higher valuation & earnings, VRPX or TRVN? Virpax Pharmaceuticals has higher earnings, but lower revenue than Trevena. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/ATrevena$443K2.18-$40.29M-$47.04-0.02 Does the MarketBeat Community favor VRPX or TRVN? Trevena received 613 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. Likewise, 68.60% of users gave Trevena an outperform vote while only 60.00% of users gave Virpax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformVirpax PharmaceuticalsOutperform Votes360.00% Underperform Votes240.00% TrevenaOutperform Votes61668.60% Underperform Votes28231.40% SummaryVirpax Pharmaceuticals beats Trevena on 6 of the 11 factors compared between the two stocks. Remove Ads Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRPX vs. The Competition Export to ExcelMetricVirpax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$323,000.00$6.42B$5.28B$7.33BDividend YieldN/A3.24%5.11%4.31%P/E RatioN/A6.7921.7017.71Price / SalesN/A225.58376.8193.06Price / CashN/A65.6738.1534.64Price / Book0.165.826.383.95Net Income-$15.19M$142.01M$3.20B$247.42M7 Day Performance8.33%6.87%4.39%3.83%1 Month Performance-93.85%-14.73%-10.03%-8.16%1 Year Performance-99.70%-10.15%10.61%0.86% Virpax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRPXVirpax Pharmaceuticals1.2902 of 5 stars$0.26+23.8%$75.00+28,746.2%-99.8%$323,000.00N/A0.007Short Interest ↑Gap UpTRVNTrevena1.2741 of 5 stars$1.22+1.9%$5.00+309.0%-88.0%$1.06M$443,000.00-0.0340NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220ERNAEterna Therapeutics2.0004 of 5 stars$0.19-1.4%N/A-91.5%$1.01M$582,000.00-0.0210Short Interest ↓News CoverageTNFATNF PharmaceuticalsN/A$0.37-1.5%N/AN/A$1.01MN/A0.006Earnings ReportPositive NewsGap UpHigh Trading VolumeEVFMEvofem Biosciences0.2031 of 5 stars$0.01-15.5%N/A-41.8%$930,000.00$11.39M-0.01120News CoverageGap DownVIRXViracta Therapeutics1.0718 of 5 stars$0.02+3.2%$4.05+17,741.4%-97.6%$902,000.00N/A-0.0220WINTWindtree Therapeutics1.6991 of 5 stars$1.20-7.7%$350.00+29,066.7%-99.7%$899,000.00N/A-0.0730Short Interest ↑MYMDMyMD PharmaceuticalsN/A$0.37-8.2%N/A-87.1%$879,000.00N/A0.006High Trading VolumeGLMDGalmed Pharmaceuticals1.0827 of 5 stars$1.24-7.5%N/A-67.4%$799,000.00N/A-0.0720Short Interest ↑ENVBEnveric Biosciences2.7789 of 5 stars$1.15-5.0%$10.00+769.6%-91.0%$780,000.00N/A-0.0320Short Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies TRVN Alternatives NMTR Alternatives ERNA Alternatives TNFA Alternatives EVFM Alternatives VIRX Alternatives WINT Alternatives MYMD Alternatives GLMD Alternatives ENVB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRPX) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRPX Stock Free VRPX Stock Alerts